• 1
    Suzuki R. Leukemia and lymphoma of natural killer cells. J Clin Exp Hematop 2005; 45: 5170.
  • 2
    Oshimi K. Progress in understanding and managing NK-cell malignancies. Br J Haematol 2007; 139: 53244.
  • 3
    Jaffe ES, Chan JK, Su IJ et al . Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas: definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996; 20: 10311.
  • 4
    Suzuki R, Suzumiya J, Nakamura S et al . Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 2004; 18: 76370.
  • 5
    Yamaguchi M, Kita K, Miwa H et al . Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995; 76: 23516.
  • 6
    Egashira M, Kawamata N, Sugimoto K, Kaneko T, Oshimi K. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 1999; 93: 599606.
  • 7
    Chim CS, Ma SY, Au WY et al . Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the international prognostic index. Blood 2004; 103: 21621.
  • 8
    Oshimi K, Kawa K, Nakamura S et al . NK-cell neoplasms in Japan. Hematology 2005; 10: 23745.
  • 9
    Lee J, Suh C, Park YH et al . Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24: 61218.
  • 10
    Yamaguchi M, Ogawa S, Nomoto Y et al . Treatment outcome of nasal NK-cell lymphoma: a report of 12 consecutively-diagnosed cases and a review of the literature. J Clin Exp Hematop 2001; 41: 939.
  • 11
    Ribrag V, Ell Hajj M, Janot F et al . Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia 2001; 15: 11236.
  • 12
    Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002; 54: 18290.
  • 13
    Koom WS, Chung EJ, Yang WI et al . Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys 2004; 59: 112737.
  • 14
    Yamaguchi M, Oguchi M, Tobinai K et al . Phase I/II study of concurrent chemoradiotherapy for newly-diagnosed, localized nasal NK/T-cell lymphoma: results of a phase I portion of JCOG0211-DI. ASH Annu Meeting Abstracts 2005; 106: 2685.
  • 15
    Murashige N, Kami M, Kishi Y et al . Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005; 130: 5617.
  • 16
    Suzuki R, Suzumiya J, Nakamura S et al . Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant 2006; 37: 42531.
  • 17
    Uno M, Tsuchiyama J, Moriwaki A et al . In vitro induction of apoptosis for nasal angiocentric natural killer cell lymphoma-derived cell line, NK-YS, by etoposide and cyclosporine A. Br J Haematol 2001; 113: 100914.
  • 18
    Lee KW, Yun T, Kim DW et al . First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/– radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk Lymphoma 2006; 47: 127482.
  • 19
    Imashuku S, Kuriyama K, Teramura T et al . Requirement for etoposide in the treatment of Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol 2001; 19: 266573.
  • 20
    Kawa K. Diagnosis and treatment of Epstein–Barr virus-associated natural killer cell lymphoproliferative disease. Int J Hematol 2003; 78: 2431.
  • 21
    Ando M, Sugimoto K, Kitoh T et al . Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol 2005; 130: 8608.
  • 22
    Nagafuji K, Fujisaki T, Arima F, Ohshima K. l-Asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol 2001; 74: 44750.
  • 23
    Yong W, Zheng W, Zhang Y et al . l-Asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 2003; 78: 1637.
  • 24
    Nowak-Gottl U, Ahlke E, Fleischhack G et al . Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood 2003; 101: 252933.
  • 25
    Aviles A, Neri N, Fernandez R, Calva A, Huerta-Guzman J, Nambo MJ. Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy. Med Oncol 2003; 20: 1317.
  • 26
    Yazawa Y, Takagi T, Asakura S, Suzuki K, Kano Y. Effects of 4-hydroperoxy ifosfamide in combination with other anticancer agents on human cancer cell lines. J Orthop Sci 1999; 4: 2317.
  • 27
    Lorico A, Boiocchi M, Rappa G, Sen S, Erba E, D’Incalci M. Increase in topoisomerase-II-mediated DNA breaks and cytotoxicity of VP16 in human U937 lymphoma cells pretreated with low doses of methotrexate. Int J Cancer 1990; 45: 15662.
  • 28
    JaffeES, HarrisNL, SteinH, VardimanJW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001.
  • 29
    World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization, 1979.
  • 30
    Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005; 19: 218694.
  • 31
    Cheson BD, Horning SJ, Coiffier B et al . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 124453.
  • 32
    Cheson BD, Pfistner B, Juweid ME et al . Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 57986.
  • 33
    Kako S, Izutsu K, Ota Y et al . FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 2007; 18: 168590.